A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare 'time and motion' (provider time spent on anemia management)
and effect on hemoglobin (Hb) levels, of methoxy polyethylene glycol-epoetin beta (Mircera)
and epoetin alfa, in anemic patients with chronic kidney disease (CKD) on hemodialysis.
Patients stable on intravenous (iv) epoetin alfa will be randomized either to receive
standard of care therapy (epoetin alfa (iv) 3 times weekly), or to receive Mircera 120-360
micrograms (iv), monthly. After a titration period, average time spent on anemia treatment
over a 3 month period will be evaluated. The anticipated time on study treatment is 3-12
months, and the target sample size is 100-500 individuals.